Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide in combination with ART for HIV-1 reservoir reactivation
NCT02902185Phase 3Unknown
- Sponsor
- Tangdu Hospital
- Start
- Nov 2016
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Chidamide + ART with Placebo + ART (2 arms). Primary endpoints: Cell-associated HIV-1 RNA at 24 weeks, Plasma HIV RNA at 96 weeks and 1 more. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02902185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02902185.